Evommune CEO Luis C. Pena acquires 1,115 shares

The ESPP purchase price was set at 85% of the issuer’s September 30, 2026 closing price.

Rhea-AI Filing Summary

Evommune, Inc. President & CEO Luis C. Pena acquired 1,115 common shares on September 30, 2026, through the non-qualified component of the company’s 2025 Employee Stock Purchase Plan. The shares were purchased at $7.02 per share, equal to 85% of the issuer’s closing price that day. Pena directly held 631,573 shares following the transaction. He reported that the transaction was reported late due to an administrative oversight.

Insider Trade Summary

Grant/Award: 1,115 shares

Grant/Award 1 txn

Insider Pena Luis C.

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Common Stock F1, F2	1,115	$7.02	$8K

Holdings After Transaction: Common Stock — 631,573 shares (Direct)

Footnotes (2)

1. F1. Represents shares acquired under the non-qualified component of the Evommune, Inc. 2025 Employee Stock Purchase Plan ("ESPP").
2. F2. In accordance with current ESPP offering standards, these shares were purchased at 85% of the closing price of the Issuer's common stock on September 30, 2026.

Key Figures

Common shares acquired: 1,115 shares Price per share: $7.02 per share Share price percentage: 85% +1 more

4 metrics

Common shares acquired 1,115 shares September 30, 2026

Price per share $7.02 per share Employee Stock Purchase Plan acquisition on September 30, 2026

Share price percentage 85% Of the issuer’s closing price on September 30, 2026

Shares held following transaction 631,573 shares Direct holdings following the September 30, 2026 transaction

Key Terms

Employee Stock Purchase Plan, non-qualified component, ESPP offering standards

3 terms

Employee Stock Purchase Plan financial

"2025 Employee Stock Purchase Plan"

An employee stock purchase plan is a company program that lets workers buy shares through small payroll deductions, often at a discount to the market price and after a set offering period. Think of it like a workplace savings plan that turns into ownership: it encourages employees to share in the company’s success and can create predictable buying or selling of stock that investors watch because it affects supply, demand and employee incentives.

non-qualified component financial

"under the non-qualified component of the Evommune, Inc. 2025 Employee Stock Purchase Plan"

ESPP offering standards financial

"In accordance with current ESPP offering standards"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

How many EVMN shares did CEO Luis C. Pena acquire, and at what price?

Luis C. Pena acquired 1,115 shares at $7.02 per share on September 30, 2026. The shares were acquired through the non-qualified component of Evommune’s 2025 Employee Stock Purchase Plan at 85% of the closing price.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 4 Insider Transactions: What Each Field Means →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Available on EDGAR 10/15/2026 - 04:29 PM EDT Accepted by SEC EDGAR 10/15/2026 - 04:28 PM EDT Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pena Luis C.

(Last) (First) (Middle)

C/O EVOMMUNE, INC.

1891 PAGE MILL ROAD

(Street)

PALO ALTO CALIFORNIA 94304

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
Evommune, Inc. [ EVMN ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	09/30/2026		A		1,115(1)	A	$7.02(2)	631,573	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents shares acquired under the non-qualified component of the Evommune, Inc. 2025 Employee Stock Purchase Plan ("ESPP").

2. In accordance with current ESPP offering standards, these shares were purchased at 85% of the closing price of the Issuer's common stock on September 30, 2026.

Remarks:

This transaction is being reported late due to an administrative oversight.

	/s/ Gregory S. Moss, Attorney-in-Fact	10/15/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)